1. Short title; table of contents (a) Short title This Act may be cited as the Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2023 or the INSULIN Act of 2023 . (b) Table of contents The table of contents for this Act is as follows: Sec. 1. Short title; table of contents. TITLE I—Commercial market patient protections Sec. 101. Requirements with respect to cost-sharing for certain insulin products. Sec. 102. Application to retiree and certain small group plans. Sec. 103. Administration. TITLE II—Pharmacy benefit manager transparency and rebate reform Sec. 201. Full rebate on insulin pass-through to plan. TITLE III—Biosimilar biological product and generic drug competition and affordability Sec. 301. Ensuring timely access to generics. Sec. 302. Permitted mid-year changes in Medicare part D plan formularies for certain biosimilar biological products and the reference product of such biosimilars. Sec. 303. Expediting competitive biosimilar competition. Sec. 304. Insulin competition report. I Commercial market patient protections 101. Requirements with respect to cost-sharing for certain insulin products (a) In general Part D of title XXVII of the Public Health Service Act ( 42 U.S.C. 300gg–111 et seq. ) is amended by adding at the end the following: 2799A–11. Requirements with respect to cost-sharing for certain insulin products (a) In general For plan years beginning on or after January 1, 2024, a group health plan or health insurance issuer offering group or individual health insurance coverage shall provide coverage of selected insulin products, and with respect to such products, shall not— (1) apply any deductible; or (2) impose any cost-sharing requirements in excess of, per 30-day supply— (A) for any applicable plan year beginning before January 1, 2025, $35; or (B) for any plan year beginning on or after January 1, 2025, the lesser of— (i) $35